Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion, in vivo study

doi:10.3748/wjg.v27.i14.1435

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 14

This Article

(242)

(295)

(0)

(10)

(2)

(6668)

(22)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Basic Study

World J Gastroenterol. Apr 14, 2021; 27(14): 1435-1450
Published online Apr 14, 2021. doi: 10.3748/wjg.v27.i14.1435

Full Size Figure Download Figure

Figure 7 Concept map of study design. GSTP: Glutathione S-transferase placental; PCNA: Proliferating cell nuclear antigen; TUBG: Tubulin; lncRNA: Long non-coding RNA.

Citation: Matboli M, Hasanin AH, Hussein R, El-Nakeep S, Habib EK, Ellackany R, Saleh LA. Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion, in vivo study. World J Gastroenterol 2021; 27(14): 1435-1450
URL: https://www.wjgnet.com/1007-9327/full/v27/i14/1435.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i14.1435

Matboli M, Hasanin AH, Hussein R, El-Nakeep S, Habib EK, Ellackany R, Saleh LA. Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion, in vivo study. World J Gastroenterol 2021; 27(14): 1435-1450 [PMID: 33911466 DOI: 10.3748/wjg.v27.i14.1435]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.